SWP
CDTX

Stratos Wealth Partners’s Cidara Therapeutics CDTX Stock Holding History

Stratos Wealth Partners’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,824
Closed -$34.4K – 1378
2023
Q3 		$34.4K Hold
1,824
– – ﹤0.01% 1262
2023
Q2 		$41.2K Buy
1,824
+1,300
+248% +$30.6K ﹤0.01% 1180
2023
Q1 		$13.3K Hold
524
– – ﹤0.01% 1121
2022
Q4 		$7.93K Hold
524
– – ﹤0.01% 1132
2022
Q3 		$7K Hold
524
– – ﹤0.01% 1114
2022
Q2 		$5K Hold
524
– – ﹤0.01% 1185
2022
Q1 		$9K Buy
+524
New +$8.89K ﹤0.01% 1261

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Stratos Wealth Partners's CDTX Position: Q4 2023 in Review

Stratos Wealth Partners sold out of Cidara Therapeutics (CDTX) in Q4 2023, closing a stake of 1,824 shares — an estimated $34.4K sold.

Stratos Wealth Partners first reported a position in CDTX in Q1 2022 and held it in 7 quarters. The position peaked at $41.2K in Q2 2023. 51 funds tracked by Wall St. Rank hold CDTX as of Q4 2023.

  • Stratos Wealth Partners reported no remaining Cidara Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Stratos Wealth Partners sold 1,824 Cidara Therapeutics shares in Q4 2023, an estimated $34.4K.
  • Stratos Wealth Partners first reported a position in Cidara Therapeutics in Q1 2022 and held it in 7 quarters.
  • Stratos Wealth Partners's Cidara Therapeutics position peaked at $41.2K in Q2 2023.
  • 51 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2023.

Based on Stratos Wealth Partners's 13F filing for Q4 2023, filed 24 Jan 2024.